Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883102 · ClinicalTrials.gov registry record · Phase 1
The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01883102: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01883102 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01883102, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study of epidermal (the outer most layer) nerve fibers (ENFs) in the skin of the body; counts of which are used to determine a disease of nerves called "small nerve fiber neuropathy." Capsaicin is approved by the Food and Drug Administration (FDA) for pain relief. Since 0.1% capsaicin is known to cause ablation (removal) of ENFs, this study will test whether such ablation results in relief of spontaneous pain, touch, or heat-pain.
Interventions
- DRUG Placebo
- DRUG Capsaicin 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT01883102 record still lists
NCT01883102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01883102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01883102 about?
NCT01883102 is a clinical study titled "The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream". This is a study of epidermal (the outer most layer) nerve fibers (ENFs) in the skin of the body; counts of which are used to determine a disease of nerves called "small nerve fiber neuropathy." Capsaicin is approved by the Food and Drug Administration (FDA) for pain relief. Since 0.1% capsaicin is ...
What is the current status of trial NCT01883102?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2013-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01883102?
The interventions under investigation include: Placebo (DRUG), Capsaicin 0.1% (DRUG).
Who is sponsoring clinical trial NCT01883102?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01883102's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia